Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Depression: HELP
Articles by Christopher S. Coffey
Based on 3 articles published since 2008

Between 2008 and 2019, Christopher Coffey wrote the following 3 articles about Depression.
+ Citations + Abstracts
1 Clinical Trial Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. 2018

Fox, Robert J / Coffey, Christopher S / Conwit, Robin / Cudkowicz, Merit E / Gleason, Trevis / Goodman, Andrew / Klawiter, Eric C / Matsuda, Kazuko / McGovern, Michelle / Naismith, Robert T / Ashokkumar, Akshata / Barnes, Janel / Ecklund, Dixie / Klingner, Elizabeth / Koepp, Maxine / Long, Jeffrey D / Natarajan, Sneha / Thornell, Brenda / Yankey, Jon / Bermel, Robert A / Debbins, Josef P / Huang, Xuemei / Jagodnik, Patricia / Lowe, Mark J / Nakamura, Kunio / Narayanan, Sridar / Sakaie, Ken E / Thoomukuntla, Bhaskar / Zhou, Xiaopeng / Krieger, Stephen / Alvarez, Enrique / Apperson, Michelle / Bashir, Khurram / Cohen, Bruce A / Coyle, Patricia K / Delgado, Silvia / Dewitt, L Dana / Flores, Angela / Giesser, Barbara S / Goldman, Myla D / Jubelt, Burk / Lava, Neil / Lynch, Sharon G / Moses, Harold / Ontaneda, Daniel / Perumal, Jai S / Racke, Michael / Repovic, Pavle / Riley, Claire S / Severson, Christopher / Shinnar, Shlomo / Suski, Valerie / Weinstock-Guttman, Bianca / Yadav, Vijayshree / Zabeti, Aram / Anonymous12481224. ·From the Mellen Center for Multiple Sclerosis, Neurological Institute (R.J.F., S. Natarajan, R.A.B., D.O.), the Imaging Institute (X.H., M.J.L., K.E.S., X.Z.), and the Department of Biomedical Engineering (P.J., K.N., B. Thoomukuntla), Cleveland Clinic, Cleveland, Ohio State University, Columbus (M.R.), and University of Cincinnati, Cincinnati (A.Z.) - all in Ohio · the Data Coordinating Center, Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), University of Iowa, Iowa City (C.S.C., J.B., D.E., E.K., M.K., J.D.L., J.Y.) · the National Institute of Neurological Disorders and Stroke, Bethesda, MD (R.C.) · the Clinical Coordinating Center, NeuroNEXT, Massachusetts General Hospital, Neurological Clinical Research Institute, Harvard Partners (M.E.C., M.M., A.A., B. Thornell), the Department of Neurology, Massachusetts General Hospital, Harvard Medical School (E.C.K.), and Brigham and Women's Hospital (C.S.), Boston · patient advocate (T.G.) and Swedish Medical Center at Seattle (P.R.), Seattle · University of Rochester Medical Center, Rochester (A.G.), Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center (S.K.), Weill Cornell Medical College (J.S.P.), Columbia University Medical Center (C.S.R.), and Montefiore Medical Center, Albert Einstein College of Medicine (S.S.), New York, State University of New York (SUNY) at Stony Brook, Stony Brook (P.K.C.), SUNY Upstate Medical University, Syracuse (B.J.), and SUNY at Buffalo, Buffalo (B.W.-G.) - all in New York · MediciNova, La Jolla (K.M.), University of California at Davis, Sacramento (M.A.), and University of California at Los Angeles, Los Angeles (B.S.G.) - all in California · Washington University School of Medicine, St. Louis (R.T.N.) · Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ (J.P.D.) · NeuroRx Research, Montreal (S. Narayanan) · the School of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN (X.Z.) · University of Colorado Denver, Aurora (E.A.) · University of Alabama at Birmingham, Birmingham (K.B.) · Feinberg School of Medicine, Northwestern University, Chicago (B.A.C.) · University of Miami Miller School of Medicine, Miami (S.D.) · University of Utah, Salt Lake City (L.D.D.) · University of Texas Southwestern Medical Center, Dallas (A.F.) · University of Virginia at Charlottesville, Charlottesville (M.D.G.) · Emory University, Atlanta (N.L.) · University of Kansas Medical Center, Kansas City (S.G.L.) · Vanderbilt University, Nashville (H.M.) · University of Pittsburgh Medical Center, Pittsburgh (V.S.) · and Oregon Health and Science University, Portland (V.Y.). ·N Engl J Med · Pubmed #30157388.

ABSTRACT: BACKGROUND: There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis. METHODS: We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg daily) or placebo for 96 weeks. The primary efficacy end point was the rate of brain atrophy, as measured by the brain parenchymal fraction (brain size relative to the volume of the outer surface contour of the brain). Major secondary end points included the change in the pyramidal tracts on diffusion tensor imaging, the magnetization transfer ratio in normal-appearing brain tissue, the thickness of the retinal nerve-fiber layer, and cortical atrophy, all measures of tissue damage in multiple sclerosis. RESULTS: Of 255 patients who underwent randomization, 129 were assigned to ibudilast and 126 to placebo. A total of 53% of the patients in the ibudilast group and 52% of those in the placebo group had primary progressive disease; the others had secondary progressive disease. The rate of change in the brain parenchymal fraction was -0.0010 per year with ibudilast and -0.0019 per year with placebo (difference, 0.0009; 95% confidence interval, 0.00004 to 0.0017; P=0.04), which represents approximately 2.5 ml less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression. CONCLUSIONS: In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942 .).

2 Article The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies. 2017

Pont-Sunyer, Claustre / Tolosa, Eduardo / Caspell-Garcia, Chelsea / Coffey, Christopher / Alcalay, Roy N / Chan, Piu / Duda, John E / Facheris, Maurizio / Fernández-Santiago, Rubén / Marek, Kenneth / Lomeña, Francisco / Marras, Connie / Mondragon, Elisabet / Saunders-Pullman, Rachel / Waro, Bjorg / Anonymous1380902. ·Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. · Neurology Unit, Hospital General de Granollers, Universitat Internacional de Catalunya, Granollers, Spain. · Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA. · Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA. · Departments of Neurology and Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, China. · Parkinson's Disease Research, Education and Clinical Center, Michael J. Crescenz VA Medical Center and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. · The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA. · Laboratory of Neurodegenerative Disorders, Department of Neurology, Hospital Clínic of Barcelona, Institutd'InvestigacionsBiomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, and the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain. · Institute for Neurodegenerative Disorders and Molecular NeuroImaging, New Haven, Connecticut, USA. · Department of Nuclear Medicine, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. · Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Toronto, Ontario, Canada. · Department of Neurology, Movement Disorders Unit. Hospital Universitario Donostia. Biodonostia Research Institute, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), San Sebastián, Guipúzcoa, Spain. · Department of Neurology, Mount Sinai Beth Israel Medical Center and Icahn School of Medicine at Mount Sinai, New York, New York, USA. · Department of Neurology, Norwegian University of Science and Technology, Trondheim, Norway. ·Mov Disord · Pubmed #28370517.

ABSTRACT: BACKGROUND: Asymptomatic, nonmanifesting carriers of leucine-rich repeat kinase 2 mutations are at increased risk of developing PD. Clinical and neuroimaging features may be associated with gene carriage and/or may demarcate individuals at greater risk for phenoconversion to PD. OBJECTIVES: To investigate clinical and dopamine transporter single-photon emission computed tomography imaging characteristics of leucine-rich repeat kinase 2 asymptomatic carriers. METHODS: A total of 342 carriers' and 259 noncarriers' relatives of G2019S leucine-rich repeat kinase 2/PD patients and 39 carriers' and 31 noncarriers' relatives of R1441G leucine-rich repeat kinase 2/PD patients were evaluated. Motor and nonmotor symptoms were assessed using specific scales and questionnaires. Neuroimaging quantitative data were obtained in 81 carriers and compared with 41 noncarriers. RESULTS: G2019S carriers scored higher in motor scores and had lower radioligand uptake compared to noncarriers, but no differences in nonmotor symptoms scores were observed. R1441G carriers scored higher in motor scores, had lower radioligand uptake, and had higher scores in depression, dysautonomia, and Rapid Eye Movements Sleep Behavior Disorder Screening Questionnaire scores, but had better cognition scores than noncarriers. Among G2019S carriers, a group with "mild motor signs" was identified, and was significantly older, with worse olfaction and lower radioligand uptake. CONCLUSIONS: G2019S and R1441G carriers differ from their noncarriers' relatives in higher motor scores and slightly lower radioligand uptake. Nonmotor symptoms were mild, and different nonmotor profiles were observed in G2019S carriers compared to R1441G carriers. A group of G2019S carriers with known prodromal features was identified. Longitudinal studies are required to determine whether such individuals are at short-term risk of developing overt parkinsonism. © 2017 International Parkinson and Movement Disorder Society.

3 Article Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. 2015

Weintraub, Daniel / Simuni, Tanya / Caspell-Garcia, Chelsea / Coffey, Christopher / Lasch, Shirley / Siderowf, Andrew / Aarsland, Dag / Barone, Paolo / Burn, David / Chahine, Lama M / Eberling, Jamie / Espay, Alberto J / Foster, Eric D / Leverenz, James B / Litvan, Irene / Richard, Irene / Troyer, Matthew D / Hawkins, Keith A / Anonymous4480822. ·Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. · Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. · Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA. · Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging, LLC (MNI), New Haven, Connecticut, USA. · Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA. · Department of Neurobiology, Care Sciences and Society and the Alzheimer Disease Research Centre, Karolinska Institutet, Stockholm, Sweden; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway. · Neurodegenerative Diseases Centre, Neuroscience Section, Department of Medicine, University of Salerno, Italy. · Institute for Ageing and Health, Newcastle University, Newcastle, England. · Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA. · Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA. · Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA. · UCSD Movement Disorder Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA. · Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. · Medivation, Inc., San Francisco, California, USA. · Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA. ·Mov Disord · Pubmed #25737166.

ABSTRACT: BACKGROUND: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. METHODS: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. RESULTS: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P < 0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P < 0.001) and apathy (P < 0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P = 0.51). CONCLUSIONS: Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS. © 2015 International Parkinson and Movement Disorder Society.